35 related articles for article (PubMed ID: 33626530)
1. Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.
Wu B; Mao ZJ; Wang Z; Wu P; Huang H; Zhao W; Zhang L; Zhang Z; Yin H; Gale RP; Yin B
Acta Haematol; 2021; 144(5):534-541. PubMed ID: 33626530
[TBL] [Abstract][Full Text] [Related]
2. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.
Kurata M; Rathe SK; Bailey NJ; Aumann NK; Jones JM; Veldhuijzen GW; Moriarity BS; Largaespada DA
Sci Rep; 2016 Nov; 6():36199. PubMed ID: 27808171
[TBL] [Abstract][Full Text] [Related]
3. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
[TBL] [Abstract][Full Text] [Related]
5. Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.
Rothenburger T; Thomas D; Schreiber Y; Wratil PR; Pflantz T; Knecht K; Digianantonio K; Temple J; Schneider C; Baldauf HM; McLaughlin KM; Rothweiler F; Bilen B; Farmand S; Bojkova D; Costa R; Ferreirós N; Geisslinger G; Oellerich T; Xiong Y; Keppler OT; Wass MN; Michaelis M; Cinatl J
J Exp Clin Cancer Res; 2021 Oct; 40(1):317. PubMed ID: 34641952
[TBL] [Abstract][Full Text] [Related]
6. Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance.
Bunimovich YL; Nair-Gill E; Riedinger M; McCracken MN; Cheng D; McLaughlin J; Radu CG; Witte ON
PLoS One; 2014; 9(8):e104125. PubMed ID: 25101980
[TBL] [Abstract][Full Text] [Related]
7. Upregulated mitosis-associated genes CENPE, CENPF, and DLGAP5 predict poor prognosis and chemotherapy resistance of Acute Myeloid Leukemia.
Shi M; Guo H; Bai Y; Niu J; Niu X; Sun K; Chen Y
Cancer Biomark; 2022; 35(1):11-25. PubMed ID: 35634845
[TBL] [Abstract][Full Text] [Related]
8. AHR signaling pathway mediates mitochondrial oxidative phosphorylation which leads to cytarabine resistance.
Jia Y; Li X; Chen L; Li L; Zhang S; Huang W; Zhang H
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):597-606. PubMed ID: 38404179
[TBL] [Abstract][Full Text] [Related]
9. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
Aimiuwu J; Wang H; Chen P; Xie Z; Wang J; Liu S; Klisovic R; Mims A; Blum W; Marcucci G; Chan KK
Blood; 2012 May; 119(22):5229-38. PubMed ID: 22517893
[TBL] [Abstract][Full Text] [Related]
10. Glucose Metabolism as a Potential Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia.
Pereira-Vieira J; Weber DD; Silva S; Barbosa-Matos C; Granja S; Reis RM; Queirós O; Ko YH; Kofler B; Casal M; Baltazar F
Pharmaceutics; 2024 Mar; 16(4):. PubMed ID: 38675105
[TBL] [Abstract][Full Text] [Related]
11. Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia.
Hatzl S; Perfler B; Wurm S; Uhl B; Quehenberger F; Ebner S; Troppmair J; Reinisch A; Wölfler A; Sill H; Zebisch A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32093419
[TBL] [Abstract][Full Text] [Related]
12. The roles and mechanisms of TGFB1 in acute myeloid leukemia chemoresistance.
Liang X; Zhou J; Li C; Wang H; Wan Y; Ling C; Pu L; Zhang W; Fan M; Hong J; Zhai Z
Cell Signal; 2024 Apr; 116():111027. PubMed ID: 38171389
[TBL] [Abstract][Full Text] [Related]
13. Human DIMT1 generates N
Shen H; Gonskikh Y; Stoute J; Liu KF
J Biol Chem; 2021 Oct; 297(4):101146. PubMed ID: 34473991
[TBL] [Abstract][Full Text] [Related]
14. microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.
Gabra MM; Salmena L
Front Oncol; 2017; 7():255. PubMed ID: 29164055
[TBL] [Abstract][Full Text] [Related]
15. Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy.
Karakitsou E; Foguet C; Contreras Mostazo MG; Kurrle N; Schnütgen F; Michaelis M; Cinatl J; Marin S; Cascante M
Comput Struct Biotechnol J; 2021; 19():4059-4066. PubMed ID: 34377370
[TBL] [Abstract][Full Text] [Related]
16. A novel approach to overcome drug resistance in acute myeloid leukemia.
Mazewski C; Platanias LC
Haematologica; 2023 Nov; 108(11):2889-2890. PubMed ID: 37165841
[No Abstract] [Full Text] [Related]
17. Targeting mRNA Decapping in AML.
Yoshimi A; Abdel-Wahab O
Cancer Cell; 2018 Mar; 33(3):339-341. PubMed ID: 29533777
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax-containing regimens in acute myeloid leukemia.
Aldoss I; Pullarkat V; Stein AS
Ther Adv Hematol; 2021; 12():2040620720986646. PubMed ID: 33628408
[TBL] [Abstract][Full Text] [Related]
19. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy.
Rodríguez-Macías G; Briz O; Cives-Losada C; Chillón MC; Martínez-Laperche C; Martínez-Arranz I; Buño I; González-Díaz M; Díez-Martín JL; Marin JJG; Macias RIR
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370755
[TBL] [Abstract][Full Text] [Related]
20. Understanding and targeting resistance mechanisms in cancer.
Lei ZN; Tian Q; Teng QX; Wurpel JND; Zeng L; Pan Y; Chen ZS
MedComm (2020); 2023 Jun; 4(3):e265. PubMed ID: 37229486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
